| Name | Title | Contact Details |
|---|
Dornier MedTech, a wholly-owned subsidiary of Accuron Medical Technology group with manufacturing headquarters in Munich, Germany, is a medical device company known for its pioneering technologies and revolutionary therapies in urology. Dornier MedTech soars thanks to its deep rooted spirit of entrepreneurship, excellence and innovation while developing some of the highest quality urology products on the market today.
NYC Health + Hospitals is the nation`s largest public health care delivery system. We are an integrated network of hospitals, trauma centers, neighborhood health centers, nursing homes, and post-acute care centers. We are a home care agency and a health plan, MetroPlus. The health system provides essential services to more than 1.4 million New Yorkers every year in more than 70 patient care locations and in their homes. Our talented workforce of more than 40,000 represents the diversity of our city and the communities we serve. The excellence of our staff, and our continued mission to care for all without exception, make us unique and rightly positioned to provide equitable, high-quality, culturally responsive, and affordable health care in every New York City community. Our promise to New Yorkers: Empower every New Yorker – without exception – to live the healthiest life possible by providing equitable, high quality, culturally responsive, and affordable health care in every community.
DePuy Mitek is a Raynham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
Omrix Biopharmeceuticals, Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.